Efficacy Rate80%
Studies3
Participants2,514
StatusAvailable
PT-141
Bremelanotide
PT-141 (Bremelanotide) is an FDA-approved melanocortin receptor agonist specifically designed to treat hypoactive sexual desire disorder in premenopausal women. Unlike other sexual health treatments, PT-141 works through the central nervous system to enhance sexual desire and arousal rather than affecting blood flow or hormones.
Clinical Safety Profile
Reported Side Effects
Nausea (40% of patients)
Flushing and warmth (20%)
Injection site reactions (13%)
Headache (11%)
Vomiting (8%)
Fatigue (4%)
Skin hyperpigmentation (rare)
Decreased appetite (3%)
Side Effect Management (Clinical Trial Data)
Nausea
Common
40%
Flushing
Common
20%
Injection Site Reaction
Occasional
13%
Headache
Occasional
11%
Vomiting
Infrequent
8%
Fatigue
Infrequent
4%
Side Effect Management Strategies
Nausea: Take with food, smaller meals, ginger supplements
Vomiting: Slower dose escalation, anti-emetics if severe
Diarrhea: Adequate hydration, probiotics, bland diet
Constipation: Increase fiber intake, adequate fluids, light exercise
Clinical Safety Metrics
Variable
Overall Safety Rating
Variable
Discontinuation Rate
Research
Approved Status
CONTRAINDICATIONS
• Uncontrolled hypertension (≥160/100 mmHg)
• Known cardiovascular disease
• Pregnancy and breastfeeding
• Known hypersensitivity to bremelanotide
Medical Disclaimer
Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.